Jefferies Group LLC Immuno Gen, Inc. Transaction History

Jefferies Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $62,231 - $113,794	-19,756 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $84,160 - $147,774	19,756 New	19,756 $7,000
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $951,615 - $1.5 Million	-200,340 Closed	0 $0
Q3 2021 Sep 21, 2023	BUY	$5.02 - $6.59 $1.01 Million - $1.32 Million	200,340 New	200,340 $1.14 Million
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $1.01 Million - $1.32 Million	200,340 New	200,340 $1.14 Million
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $36,540 - $66,990	-20,300 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $48,923 - $119,973	20,300 New	20,300 $55,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.